Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Kevin Joseph Fitzgerald sold 1,598 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $523,584.70. Following the completion of the transaction, the executive vice president owned 23,512 shares in the company, valued at $7,703,706.80. This trade represents a 6.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Kevin Joseph Fitzgerald also recently made the following trade(s):
- On Tuesday, March 3rd, Kevin Joseph Fitzgerald sold 1,652 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $319.73, for a total transaction of $528,193.96.
- On Tuesday, February 17th, Kevin Joseph Fitzgerald sold 2,041 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $331.96, for a total transaction of $677,530.36.
- On Friday, February 13th, Kevin Joseph Fitzgerald sold 1,959 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $310.08, for a total transaction of $607,446.72.
- On Tuesday, January 13th, Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $370.33, for a total value of $848,055.70.
- On Monday, January 12th, Kevin Joseph Fitzgerald sold 1,510 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $362.87, for a total value of $547,933.70.
Alnylam Pharmaceuticals Stock Performance
NASDAQ ALNY traded down $0.80 on Thursday, hitting $326.50. 74,844 shares of the company traded hands, compared to its average volume of 1,448,643. The business's 50 day moving average price is $355.63 and its 200-day moving average price is $416.41. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The company has a market capitalization of $43.30 billion, a price-to-earnings ratio of 190.94 and a beta of 0.36.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same period last year, the business earned ($0.65) EPS. The firm's quarterly revenue was up 84.9% compared to the same quarter last year. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.
More Alnylam Pharmaceuticals News
Here are the key news stories impacting Alnylam Pharmaceuticals this week:
- Positive Sentiment: Strategic research collaboration with Tenaya Therapeutics to discover cardiovascular genetic targets; deal includes up to $10M in upfront payments plus research funding and up to $1.13B in milestones — expands Alnylam’s RNAi target pipeline into cardiovascular disease and could add high‑value, long‑term opportunities. Tenaya collaboration
- Positive Sentiment: Reported reimbursement win and favorable trial progress noted in recent coverage — improves near‑term commercial visibility for approved RNAi drugs and supports the view that current valuation may underprice upcoming revenue drivers. Reimbursement and trial progress
- Positive Sentiment: Industry tailwind: a large orphan‑drug market outlook reinforces long‑term demand for Alnylam’s rare‑disease franchises, supporting sustained growth potential for marketed and pipeline RNAi therapies. Orphan‑drug market
- Neutral Sentiment: Former Alnylam CEO John Maraganore joined Protego Biopharma’s board — notable industry movement but not directly material to Alnylam’s operations. Maraganore appointment
- Neutral Sentiment: Short‑interest data reported as zero shares appears to be a reporting glitch (days‑to‑cover shown as 0.0); unlikely to be a real driver of positioning today.
- Negative Sentiment: Significant insider selling by the CEO and multiple EVPs (sales reported March 2–3, including CEO Yvonne Greenstreet and several senior execs); while insiders retain large holdings, the clustered sales (disclosed proceeds in the low‑millions) can create near‑term negative sentiment and selling pressure. CEO SEC filing InsiderTrades summary
Analysts Set New Price Targets
A number of analysts have recently issued reports on the stock. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Thursday, January 15th. Royal Bank Of Canada cut their price target on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an "outperform" rating for the company in a research note on Tuesday, January 20th. Needham & Company LLC decreased their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a "buy" rating on the stock in a report on Thursday, February 12th. Leerink Partners dropped their price objective on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a "market perform" rating for the company in a research note on Monday, December 15th. Finally, Raymond James Financial reiterated an "outperform" rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $477.96.
Get Our Latest Stock Report on ALNY
Hedge Funds Weigh In On Alnylam Pharmaceuticals
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Root Financial Partners LLC bought a new stake in Alnylam Pharmaceuticals in the third quarter worth $25,000. MV Capital Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $25,000. Salomon & Ludwin LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $27,000. HM Payson & Co. bought a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $27,000. Finally, Golden State Wealth Management LLC raised its position in Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 36 shares during the period. 92.97% of the stock is owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
(
Get Free Report)
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
